Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
1.
Allergy ; 71(8): 1181-91, 2016 08.
Artículo en Inglés | MEDLINE | ID: mdl-26999633

RESUMEN

BACKGROUND: Pollen-food syndrome (PFS) is heterogeneous with regard to triggers, severity, natural history, comorbidities, and response to treatment. Our study aimed to classify different endotypes of PFS based on IgE sensitization to panallergens. METHODS: We examined 1271 Italian children (age 4-18 years) with seasonal allergic rhinoconjunctivitis (SAR). Foods triggering PFS were acquired by questionnaire. Skin prick tests were performed with commercial pollen extracts. IgE to panallergens Phl p 12 (profilin), Bet v 1 (PR-10), and Pru p 3 (nsLTP) were tested by ImmunoCAP FEIA. An unsupervised hierarchical agglomerative clustering method was applied within PFS population. RESULTS: PFS was observed in 300/1271 children (24%). Cluster analysis identified five PFS endotypes linked to panallergen IgE sensitization: (i) cosensitization to ≥2 panallergens ('multi-panallergen PFS'); (ii-iv) sensitization to either profilin, or nsLTP, or PR-10 ('mono-panallergen PFS'); (v) no sensitization to panallergens ('no-panallergen PFS'). These endotypes showed peculiar characteristics: (i) 'multi-panallergen PFS': severe disease with frequent allergic comorbidities and multiple offending foods; (ii) 'profilin PFS': oral allergy syndrome (OAS) triggered by Cucurbitaceae; (iii) 'LTP PFS': living in Southern Italy, OAS triggered by hazelnut and peanut; (iv) 'PR-10 PFS': OAS triggered by Rosaceae; and (v) 'no-panallergen PFS': mild disease and OAS triggered by kiwifruit. CONCLUSIONS: In a Mediterranean country characterized by multiple pollen exposures, PFS is a complex and frequent complication of childhood SAR, with five distinct endotypes marked by peculiar profiles of IgE sensitization to panallergens. Prospective studies in cohorts of patients with PFS are now required to test whether this novel classification may be useful for diagnostic and therapeutic purposes in the clinical practice.


Asunto(s)
Alérgenos/inmunología , Conjuntivitis Alérgica/diagnóstico , Hipersensibilidad a los Alimentos/diagnóstico , Alimentos/efectos adversos , Polen/inmunología , Rinitis Alérgica Estacional/diagnóstico , Adolescente , Edad de Inicio , Niño , Preescolar , Análisis por Conglomerados , Comorbilidad , Conjuntivitis Alérgica/epidemiología , Conjuntivitis Alérgica/inmunología , Femenino , Hipersensibilidad a los Alimentos/epidemiología , Hipersensibilidad a los Alimentos/inmunología , Humanos , Inmunoglobulina E/sangre , Inmunoglobulina E/inmunología , Italia/epidemiología , Masculino , Vigilancia de la Población , Rinitis Alérgica Estacional/epidemiología , Rinitis Alérgica Estacional/inmunología , Factores de Riesgo , Estaciones del Año , Pruebas Cutáneas , Síndrome
3.
Biochim Biophys Acta ; 1757(9-10): 1421-8, 2006.
Artículo en Inglés | MEDLINE | ID: mdl-16814248

RESUMEN

The expressional profile of mitochondrial transcripts and of genes involved in the mitochondrial biogenesis pathway induced by ALCAR daily supplementation in soleus muscle of control and unloaded 3-month-old rats has been analyzed. It has been found that ALCAR treatment is able to upregulate the expression level of mitochondrial transcripts (COX I, ATP6, ND6, 16 S rRNA) in both control and unloaded animals. Interestingly, ALCAR feeding to unloaded rats resulted in the increase of transcript level for master factors involved in mitochondrial biogenesis (PGC-1alpha, NRF-1, TFAM). It also prevented the unloading-induced downregulation of mRNA levels for kinases able to transduce metabolic (AMPK) and neuronal stimuli (CaMKIIbeta) into mitochondrial biogenesis. No significant effect on the expressional level of such genes was found in control ALCAR-treated rats. In addition, ALCAR feeding was able to prevent the loss of mitochondrial protein content due to unloading condition. Correlation analysis revealed a strong coordination in the expression of genes involved in mitochondrial biogenesis only in ALCAR-treated suspended animals, supporting a differentiated effect of ALCAR treatment in relation to the loading state of the soleus muscle. In conclusions, we demonstrated the ability of ALCAR supplementation to promote only in soleus muscle of hindlimb suspended rats an orchestrated expression of genes involved in mitochondrial biogenesis, which might counteract the unloading-induced metabolic changes, preventing the loss of mitochondrial proteins.


Asunto(s)
Acetilcarnitina/administración & dosificación , Acetilcarnitina/farmacología , Regulación de la Expresión Génica/efectos de los fármacos , Genes Mitocondriales/genética , Suspensión Trasera/fisiología , Mitocondrias Musculares/efectos de los fármacos , Músculo Esquelético/efectos de los fármacos , Animales , Núcleo Celular/metabolismo , Femenino , Mitocondrias Musculares/fisiología , Proteínas Mitocondriales/genética , Proteínas Mitocondriales/metabolismo , Músculo Esquelético/metabolismo , Coactivador 1-alfa del Receptor Activado por Proliferadores de Peroxisomas gamma , ARN Mensajero/genética , ARN Mensajero/metabolismo , Proteínas de Unión al ARN/genética , Ratas , Ratas Wistar , Factores de Transcripción/genética
4.
Int J Tissue React ; 24(3): 89-96, 2002.
Artículo en Inglés | MEDLINE | ID: mdl-12635861

RESUMEN

Evidence is accumulating that intermediates of oxygen reduction may be associated with the development of alcoholic disease. Free radical-induced perturbation of the oxidant/antioxidant balance in the cell is widely recognized as the main causative factor of age-related disorders. In the present study we investigated the effects of 20 months of ethanol consumption on the antioxidant defense system in different rat organs compared with normal aging in the absence and presence of treatment with L-acetyl carnitine. We demonstrate that aged rats underwent significant perturbation of the antioxidant defense system, as indicated by depletion of reduced glutathione (GSH) content, increased oxidized GSH, free radical-induced luminescence associated with increased hydroxynonenal content and decreased GSH reductase activity. These modifications, observed particularly in brain and liver compared with other organs, were enhanced by long-term alcohol exposure and, interestingly, were significantly reduced with acetyl carnitine supplements. Our results indicate that decreased GSH reductase activity and thiol depletion are important factors in effecting a pathogenic role for oxidative stress in aging and in all situations in which age-correlated and oxidant-induced changes occur, such as in alcoholism. Administration of acetyl carnitine greatly reduces these metabolic abnormalities. Our findings support its pharmacological potential in the management of alcoholic disturbances.


Asunto(s)
Acetilcarnitina/farmacología , Encéfalo/efectos de los fármacos , Etanol/farmacología , Hígado/efectos de los fármacos , Administración Oral , Factores de Edad , Aldehídos/metabolismo , Animales , Antioxidantes/metabolismo , Encéfalo/metabolismo , Antagonismo de Drogas , Etanol/administración & dosificación , Glutatión/metabolismo , Glutatión Reductasa/metabolismo , Hígado/metabolismo , Mediciones Luminiscentes , Masculino , Oxidación-Reducción/efectos de los fármacos , Estrés Oxidativo , Ratas , Ratas Wistar
5.
Int J Tissue React ; 24(3): 97-104, 2002.
Artículo en Inglés | MEDLINE | ID: mdl-12635862

RESUMEN

Chronic alcoholism is a major public health problem and causes multiorgan diseases and toxicity. Although the majority of ethanol ingested is metabolized by the liver, it has intoxicating effects in the brain. Evidence is accumulating that intermediates of oxygen reduction may be associated with the development of alcoholic disease. Several studies have shown the capacity of carnitine and its derivatives to influence ethanol metabolism. We have previously demonstrated that preadministration of L-carnitine to rats receiving ethanol significantly reduced fatty acid ethyl esters in different organs and that the carnitine/acylcarnitine system is crucial for maintaining a functional acetyl-CoA/CoA ratio under conditions in which cellular homeostasis is exposed to the deleterious effects of accumulating organic acids. Ethanol, administered to rats for 20 months, induced significant changes in the status of glutathione, primarily in the brain regions of hippocampus and cerebellum, followed by cortex and striatum, where a decrease in reduced glutathione (GSH) and the GSH/oxidized glutathione ratio was found. The same brain regions showed a significant increase in free radical-induced luminescence and hydroxynonenal (HNE), which were associated with decreased GSH reductase activity. Long-term supplementation with acetyl carnitine significantly reduced GSH depletion, particularly in the brain regions of hippocampus, an effect associated with decreased luminescence and HNE formation. In addition, acetyl carnitine treatment increased GSH reductase and arginase activities. Our results indicate that decreased GSH reductase activities associated with thiol depletion are important factors sustaining a pathogenic role in alcohol-related pathologies. Administration of acetyl carnitine greatly reduces these metabolic abnormalities. This evidence supports the pharmacological potential of acetyl carnitine in the management of alcoholic disturbances.


Asunto(s)
Acetilcarnitina/farmacología , Mapeo Encefálico , Encéfalo/efectos de los fármacos , Etanol/farmacología , Administración Oral , Factores de Edad , Aldehídos/metabolismo , Animales , Antioxidantes/metabolismo , Encéfalo/metabolismo , Antagonismo de Drogas , Etanol/administración & dosificación , Glutatión/metabolismo , Glutatión Reductasa/metabolismo , Mediciones Luminiscentes , Masculino , Oxidación-Reducción/efectos de los fármacos , Estrés Oxidativo , Ratas , Ratas Wistar
7.
Eur J Pediatr ; 160(5): 288-92, 2001 May.
Artículo en Inglés | MEDLINE | ID: mdl-11388596

RESUMEN

UNLABELLED: A 15-year-old boy with epilepsy and cerebral calcifications, treated with valproic acid, ethyl phenylbarbiturate and ethosuximide, was referred for drug induced systemic lupus erythematosus. Anti-gliadin (AGA) and anti-endomysium (EMA) antibody tests were both positive (EMA titre 1:50). Endoscopic duodenal biopsy showed intense chronic inflammation without villous atrophy or crypt hyperplasia. The child was discharged with a gluten-containing diet. The follow-up showed an increase in EMA titre (1:200) and the persistence of AGA. After 15 months, a second endoscopic intestinal biopsy showed flat mucosa and villous atrophy. Three serum folic acid determinations showed 1.8, 2.4, 2.0 ng/ml (reference range 2.5-16.9 ng/ml) prior to the two intestinal biopsies, but returned to normal levels (11.8 ng/ml) after a gluten-free diet and oral supplementation together. Two years later, the frequency of epileptic seizures was unchanged despite ongoing anti-epileptic treatment and a gluten-free diet. As cerebral calcification and epilepsy are reminiscent of the findings in congenital folate malabsorption, oral loading tests with 5 mg folic acid were carried out and showed impaired intestinal absorption and a defect in the transport across the blood-brain barrier. Low CSF folate levels (13.9 and 12.6 ng/ml, reference range 15-40 ng/ml) and an alteration in the CSF/serum folate ratio (1.43 and 1.16, normal ratio 3:1) were also found as well as increased levels of cystathionine both in CSF (40 micromol/l, reference range 18-28 micromol/l) and in serum (32 micromol/l, reference value <0.10 micromol/l). CONCLUSION: Impairment of intestinal folic acid absorption with a defect in folic acid transport across the blood-brain barrier has been demonstrated in a case of epilepsy and cerebral calcifications associated with coeliac disease.


Asunto(s)
Anticonvulsivantes/efectos adversos , Barrera Hematoencefálica , Encefalopatías/complicaciones , Encéfalo/patología , Calcinosis/complicaciones , Enfermedad Celíaca/complicaciones , Enfermedad Celíaca/diagnóstico , Epilepsia/tratamiento farmacológico , Ácido Fólico/metabolismo , Lupus Eritematoso Sistémico/inducido químicamente , Adolescente , Transporte Biológico , Encéfalo/metabolismo , Encefalopatías/metabolismo , Calcinosis/metabolismo , Enfermedad Celíaca/metabolismo , Epilepsia/complicaciones , Etosuximida/efectos adversos , Ácido Fólico/administración & dosificación , Ácido Fólico/sangre , Ácido Fólico/líquido cefalorraquídeo , Humanos , Lupus Eritematoso Sistémico/complicaciones , Lupus Eritematoso Sistémico/metabolismo , Masculino , Urea/efectos adversos , Urea/análogos & derivados , Ácido Valproico/efectos adversos
8.
Neurochem Res ; 22(3): 257-65, 1997 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-9051659

RESUMEN

Cerebellar granule cells (CGC) at different stages of maturation in vitro (1 or 6 DIV), were treated with beta 25-35 and acetyl-L-carnitine arginine amide (ST857) in presence of 25 mM KCl in the culture medium, and neuronal viability was assessed. Three days of treatment slightly modified the survival of 1 DIV-treated cells, which degenerate and die five days later beta-amyloid matching. Similarly, a significative neurotoxic effect was observed on 6 DIV treated-cells after 5 days of exposure to the peptide, while the death occurred within 8 days. ST857 coincubated with beta 25-35 was able to rescue neurons from beta 25-35-induced neurotoxicity. We also studied the changes in Ca2+ homeostasis following glutamate stimulation, in control and beta-amyloid treated single cells, either in presence or in absence of ST857. beta 25-35 did not affect basal [Ca2+]i, while modified glutamate-induced [Ca2+]i increase, causing a sustained plateau phase of [Ca2+]i, that persisted after the removal of the agonist. ST857 pretreatment completely reverted this effect suggesting that, in CGC chronically treated with beta 25-35, ST857 could protect the cells by neurotoxic insults of the peptide likely interfering with the cellular mechanisms involved in the control of Ca2+ homeostasis.


Asunto(s)
Acetilcarnitina/análogos & derivados , Péptidos beta-Amiloides/toxicidad , Arginina/análogos & derivados , Cerebelo/efectos de los fármacos , Factores de Crecimiento Nervioso/farmacología , Neuronas/efectos de los fármacos , Neurotoxinas/toxicidad , Fragmentos de Péptidos/toxicidad , Acetilcarnitina/farmacología , Péptidos beta-Amiloides/antagonistas & inhibidores , Animales , Arginina/farmacología , Metabolismo Basal , Células Cultivadas , Cerebelo/citología , Evaluación Preclínica de Medicamentos , Ácido Glutámico/farmacología , Homeostasis/efectos de los fármacos , Degeneración Nerviosa/efectos de los fármacos , Neurotoxinas/antagonistas & inhibidores , Fragmentos de Péptidos/antagonistas & inhibidores , Ratas , Ratas Wistar , Grabación en Video
9.
Eur Neurol ; 24(4): 262-71, 1985.
Artículo en Inglés | MEDLINE | ID: mdl-4006995

RESUMEN

The acute effects of intravenously administered L-acetylcarnitine (L-AC) were evaluated in 5 healthy and 20 diseased volunteers (17 vascular, 3 tumoral cerebral lesions). Short-latency scalp somatosensory-evoked potentials (SEPs) to simultaneous median, and separate unilateral peroneal nerve stimulation were carried out before and after L-AC administration (at 10-, 30- and 60-min intervals). L-AC did not influence peak and interpeak latencies; however, in a percentage of healthy and diseased volunteers a clear-cut amplitude increase was evident affecting all those peaks generated between the thalamus and the cortex. While in normal and tumoral volunteers the voltage increase was bilaterally balanced, the amplitude increments were more evident on the 'affected' hemisphere in vascular patients, partially reversing the abnormal amplitude ratios between homologous peaks on 'healthy' and 'affected' hemispheres. In no case were transient clinical changes, either of an objective or subjective nature, associated with SEP amplitude changes; these were still present at the 60th minute, having reached their nadir at the 30th minute in 'responders'.


Asunto(s)
Acetilcarnitina/uso terapéutico , Neoplasias Encefálicas/tratamiento farmacológico , Carnitina/análogos & derivados , Trastornos Cerebrovasculares/tratamiento farmacológico , Potenciales Evocados Somatosensoriales , Adulto , Anciano , Neoplasias Encefálicas/fisiopatología , Corteza Cerebral/fisiopatología , Trastornos Cerebrovasculares/fisiopatología , Femenino , Humanos , Masculino , Nervio Mediano/fisiopatología , Persona de Mediana Edad , Vías Nerviosas/fisiopatología , Sensación/fisiología , Tálamo/fisiopatología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA